REG - C4X Discovery - Appointment of Dr Cathy Tralau-Stewart as CSO

C4X Discovery HoldingsAnnouncement

21/12/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211221:nRSU2587Wa&default-theme=true

RNS Number : 2587W  C4X Discovery Holdings PLC  21 December 2021

C4X Discovery Holdings plc

 

("C4XD", "C4X Discovery" or the "Company")

 

Dr Catherine Tralau-Stewart Appointed as C4XD's Chief Scientific Officer

 

21 December 2021 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug
Discovery company, today announces the appointment of Dr Catherine Jane
Tralau-Stewart, PhD, FRSC, as Chief Scientific Officer ("CSO"), as of 4
January 2022.

 

Cathy joins C4XD with more than 20 years of senior academic and industry
leadership experience. Her broad and in-depth knowledge of drug discovery and
translation of early research innovation into robust drug discovery programmes
has enabled the development of scientific portfolios as well as the design and
negotiation of many initiatives to support effective decision-making.
Previously she was Senior Director, Alliances, for Takeda Pharmaceuticals
where she was responsible for and contributed to the strategic development and
management of academic alliances for Takeda for the US, Australia, Japan and
Europe.  Having started her career at GSK, she moved into academia where she
held senior leadership roles building drug discovery portfolios through to
Phase III clinical studies, at Imperial College London, University of
California San Francisco and Stanford University-Takeda Alliance for
Innovative Medicines.

 

Cathy has a BSc (Hons) Biological Sciences (Biochemistry/Pharmacology) and a
PhD (Clinical Sciences) University College Hospital Medical School, National
Medical Laser Centre, Dept. of Surgery and ICRF (CRUK).  She has been
involved in advising on, evaluation and due diligence of over 500 projects and
has supported and facilitated the translation of over 40 therapeutic
technologies towards the clinic from academia and delivered strategies with
effective milestone driven decision-making. Cathy is expert in transforming
therapeutics projects from target identification and validation through lead
optimisation to Clinical Proof of Concept in many therapeutic areas including
Inflammation and Neurosciences. She has published more than 25 publications
and is the inventor of three granted patents and is a non-inventor contributor
of many more.

Cathy received the President's award of Fellow Royal Society of Chemistry
(FRSC), is International Meeting Chair 2022 & Previous Invited Board
Director Society of Laboratory Screening & Automation (SLAS), Fellow of
SLAS, Member of British Pharmacological Society, is currently supporting the
development of Closed Loop Medicine's commercial Steering Group and has acted
as advisor to many academic entrepreneurship & commercialization
programmes including Stanford SPARK, UCSF, UCLA, UCSD, UC Davis and the NIH.

 

Clive Dix, Chief Executive Officer of C4X Discovery, commented: "Cathy is a
highly respected scientific leader with strong and deep drug discovery
expertise and we are delighted and proud that she will be joining the team
here at C4XD. Her experience in building drug discovery portfolios and
advancing programmes into clinical development will enhance the work of the
team here at C4XD and expand our portfolio through her strong academic and
industry network. We warmly welcome Cathy and look forward to working
alongside her."

 

Cathy Tralau-Stewart added: "This is a fantastic opportunity to work at an
innovative, Drug Discovery company with cutting-edge technologies and an
inspirational scientific team. C4XD has made incredible progress to date and I
am excited to be joining the team to build on and advance the portfolio
towards future commercial partnership that could improve the lives of patients
in need of new treatment options."

 

- Ends -

 

 

Contacts

 

 C4X Discovery Holdings
 Mo Noonan, Communications                                 +44 (0)787 6444977

 Panmure Gordon (UK) Limited (NOMAD and Broker)
 Freddy Crossley, Emma Earl (Corporate Finance)            +44 (0)20 7886 2500
 Rupert Dearden (Corporate Broking)

 C4X Discovery Media - Consilium Strategic Communications
 Mary-Jane Elliott, Chris Gardner, Matthew Neal            +44 (0)203 709 5700

 

Notes to Editors:

 

About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining
scientific expertise with cutting-edge Drug Discovery technologies to
efficiently deliver world leading medicines, which are developed by our
partners for the benefit of patients. We have a highly valuable and
differentiated approach to Drug Discovery through our enhanced DNA-based
target identification and candidate molecule design capabilities, generating
small molecule drug candidates across multiple disease areas including
inflammation, oncology, neurodegeneration and addictive disorders. Our
commercially attractive portfolio ranges from early-stage novel target
opportunities to late-stage Drug Discovery programmes ready for out-licensing
to partners and we have two commercially partnered programmes with one
candidate in clinical development.

 

We collaborate with leading pharmaceutical and life sciences companies to
enrich our expertise and take our assets through pre-clinical and clinical
development. Through early-stage revenue-generating licensing deals, we
realise returns from our high value pre-clinical assets which are reinvested
to maximise the value of our Drug Discovery portfolio.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPPGGUPUPGGMU